Eyecare Innovations Today: An Ophthalmic Educational Podcast Series

Navigating the Impact of Preservatives in Ophthalmic Medications: Insights From Dr. Robert J. Noecker

13 min · 7 jun 2024
aflevering Navigating the Impact of Preservatives in Ophthalmic Medications: Insights From Dr. Robert J. Noecker artwork

Beschrijving

In this episode, Robert J. Noecker, MD, reviews the role of preservatives, particularly benzalkonium chloride (BAK), in ophthalmic medications. While BAK effectively prevents bacterial growth, its inherent toxicity poses challenges with prolonged use, leading to symptoms associated with ocular surface diseases. Dr. Noecker emphasizes the importance of exploring alternatives like preservative-free formulations or less toxic oxidizing preservatives, which should ensure effective glaucoma treatment without compromising ocular health. This activity is supported by an independent medical education grant from Théa Pharma.

Reacties

0

Wees de eerste die een reactie plaatst

Meld je nu aan en word lid van de Eyecare Innovations Today: An Ophthalmic Educational Podcast Series community!

Probeer gratis

Probeer 14 dagen gratis

€ 9,99 / maand na proefperiode. · Elk moment opzegbaar.

  • Podcasts die je alleen op Podimo hoort
  • 20 uur luisterboeken / maand
  • Gratis podcasts

Alle afleveringen

65 afleveringen

aflevering The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer artwork

The European Approach to Preservative-Free Pharmaceuticals: A Conversation With Dr. Anton Hommer

In this episode, Anton Hommer, MD, discusses the European perspective on adopting preservative-free pharmaceuticals, highlighting challenges like health care professionals’ reluctancy to change, diverse reimbursement systems, and higher costs. He compares single-use and multiuse drugs, considering factors such as environmental impact and cost-effectiveness. Dr. Hommer emphasizes the superior efficacy of preservative-free medications, especially in treating chronic conditions such as glaucoma, and anticipates an increase in their use to protect ocular health and enhance chronic disease management. This activity is supported by an independent medical education grant from Théa Pharma.

4 jun 202411 min